Moderna (NASDAQ:MRNA) Posts Earnings Results, Beats Expectations By $0.52 EPS

Moderna (NASDAQ:MRNA) released its earnings results on Thursday. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52, Briefing.com reports. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same period in the prior year, the firm earned $0.19 earnings per share. The business’s quarterly revenue was down 91.0% compared to the same quarter last year.

Moderna Trading Down 0.5 %

NASDAQ:MRNA opened at $125.00 on Friday. The company has a market capitalization of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. The company has a quick ratio of 3.36, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna has a 52-week low of $62.55 and a 52-week high of $142.79. The stock has a fifty day simple moving average of $105.05 and a 200-day simple moving average of $94.42.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MRNA. HSBC restated a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer upped their target price on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research note on Friday. Canaccord Genuity Group increased their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday. Finally, Royal Bank of Canada increased their price target on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Friday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $129.55.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the sale, the director now owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the sale, the director now owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 647 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock valued at $14,822,576 in the last 90 days. 15.70% of the stock is currently owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.